The forecast for Germany's erythromycin imports from 2024 through 2028 suggests a gradual decline in volume, decreasing from 65.56 thousand kilograms in 2024 to 61.96 thousand kilograms by 2028. This implies a declining interest or potential substitution in antibiotics or changes in medical guidelines. In 2023, the volume of imports was consistent, emphasizing a recent shift starting from 2024. The average yearly decrease over this period is steady, reflecting a compounded annual growth rate (CAGR) decline.
Future trends to watch include regulatory changes in pharmaceutical imports, shifts in domestic production capabilities, and advancements in alternative antibiotics that could further impact erythromycin demand in Germany. Continuous monitoring of EU pharmaceutical policies will also be pivotal. Additionally, changes in global supply chain dynamics could alter import volumes.
